These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 20949375)

  • 1. Tufted hair folliculitis in a woman treated with trastuzumab.
    Rosman IS; Anadkat MJ
    Target Oncol; 2010 Dec; 5(4):295-6. PubMed ID: 20949375
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tufted hair folliculitis in a woman treated with lapatinib for breast cancer.
    Ena P; Fadda GM; Ena L; Farris A; Santeufemia DA
    Clin Exp Dermatol; 2008 Nov; 33(6):790-1. PubMed ID: 18627387
    [No Abstract]   [Full Text] [Related]  

  • 3. [Cutaneous side effects of EGF receptor inhibitors].
    Nassar D; Soutou B; Aractingi S
    Bull Cancer; 2009 Dec; 96 Suppl():S85-91. PubMed ID: 20034874
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Severe folliculitis with secondary impetiginization in the scalp of a woman treated with panitumumab.
    Rodríguez Bandera AI; Gómez Fernández C; Vorlicka K; Ruiz-Bravo Burguillo E; Herranz Pinto P
    Int J Dermatol; 2015 Jun; 54(6):e226-9. PubMed ID: 25040914
    [No Abstract]   [Full Text] [Related]  

  • 5. Spotlight on trastuzumab as adjuvant treatment in human epidermal growth factor receptor 2 (HER2)-positive early breast cancer.
    Garnock-Jones KP; Keating GM; Scott LJ
    BioDrugs; 2010 Jun; 24(3):207-9. PubMed ID: 20462285
    [No Abstract]   [Full Text] [Related]  

  • 6. Phytomenadione pre-treatment in EGFR inhibitor-induced folliculitis.
    Tomková H; Pospíšková M; Zábojníková M; Kohoutek M; Serclová M; Gharibyar M; Sternberský J
    J Eur Acad Dermatol Venereol; 2013 Apr; 27(4):514-9. PubMed ID: 22035385
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sensitization of chemotherapy by anti-HER.
    Kataoka A; Ishida M; Murakami S; Ohno S
    Breast Cancer; 2004; 11(2):105-15. PubMed ID: 15550854
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The role of trastuzumab in early stage breast cancer: current data and treatment recommendations.
    Lin A; Rugo HS
    Curr Treat Options Oncol; 2007 Feb; 8(1):47-60. PubMed ID: 17660958
    [TBL] [Abstract][Full Text] [Related]  

  • 9. EGFR inhibitor-associated acneiform folliculitis: assessment and management.
    Duvic M
    Am J Clin Dermatol; 2008; 9(5):285-94. PubMed ID: 18717603
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Trastuzumab and breast cancer: developments and current status.
    Tokunaga E; Oki E; Nishida K; Koga T; Egashira A; Morita M; Kakeji Y; Maehara Y
    Int J Clin Oncol; 2006 Jun; 11(3):199-208. PubMed ID: 16850126
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Tykerb for breast cancer].
    Suzuki Y; Saito Y; Okamura T; Tokuda Y
    Gan To Kagaku Ryoho; 2011 Jun; 38(6):892-5. PubMed ID: 21677477
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Controversies in the use of adjuvant trastuzumab (Herceptin).
    Chowdhury S; Pickering L; Ellis P
    J Br Menopause Soc; 2006 Dec; 12(4):172-4. PubMed ID: 17178019
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Clinical implications of trastuzumab].
    Saeki T; Takashima S
    Gan To Kagaku Ryoho; 2003 Aug; 30(8):1094-9. PubMed ID: 12938263
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of trastuzumab in the adjuvant treatment of HER2-positive early breast cancer.
    Haq B; Geyer CE
    Womens Health (Lond); 2009 Mar; 5(2):135-47. PubMed ID: 19245352
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Role of trastuzumab in adjuvant therapy for locally invasive breast cancer.
    Kabe KL; Kolesar JM
    Am J Health Syst Pharm; 2006 Mar; 63(6):527-33. PubMed ID: 16522889
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of trastuzumab.
    Jones RL; Smith IE
    Expert Opin Drug Saf; 2004 Jul; 3(4):317-27. PubMed ID: 15268649
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reversible and irreversible cardiac dysfunction associated with trastuzumab in breast cancer.
    Tham YL; Verani MS; Chang J
    Breast Cancer Res Treat; 2002 Jul; 74(2):131-4. PubMed ID: 12186373
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Trastuzumab plus vinorelbine or taxane chemotherapy for HER2-overexpressing metastatic breast cancer: the trastuzumab and vinorelbine or taxane study.
    Burstein HJ; Keshaviah A; Baron AD; Hart RD; Lambert-Falls R; Marcom PK; Gelman R; Winer EP
    Cancer; 2007 Sep; 110(5):965-72. PubMed ID: 17614302
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mitral regurgitation due to papillary muscle dyssynchrony during trastuzumab treatment.
    Karabay CY; Kocabay G; Kalayci A; Zehir R; Tanboga H
    Cardiology; 2010; 117(4):296-300. PubMed ID: 21358201
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Trastuzumab: a review of its use in the management of HER2-positive metastatic and early-stage breast cancer.
    Plosker GL; Keam SJ
    Drugs; 2006; 66(4):449-75. PubMed ID: 16597163
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.